Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
28.04
-0.18 (-0.64%)
May 8, 2025, 4:00 PM EDT - Market closed
Agios Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Agios Pharmaceuticals stock have an average target of 56, with a low estimate of 46 and a high estimate of 71. The average target predicts an increase of 99.71% from the current stock price of 28.04.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Agios Pharmaceuticals stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Maintains $74 → $71 | Buy | Maintains | $74 → $71 | +153.21% | May 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $58 | Strong Buy | Reiterates | $58 | +106.85% | Feb 24, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Dec 18, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $55 → $57 | Buy | Maintains | $55 → $57 | +103.28% | Dec 10, 2024 |
| Scotiabank | Scotiabank | Buy Maintains $53 → $75 | Buy | Maintains | $53 → $75 | +167.48% | Dec 9, 2024 |
Financial Forecast
Revenue This Year
51.32M
from 36.50M
Increased by 40.62%
Revenue Next Year
162.31M
from 51.32M
Increased by 216.26%
EPS This Year
-7.63
from 11.64
EPS Next Year
-6.49
from -7.63
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 82.2M | 215.4M | 556.6M | ||
| Avg | 51.3M | 162.3M | 365.7M | ||
| Low | 41.0M | 108.5M | 228.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 125.3% | 319.7% | 242.9% | ||
| Avg | 40.6% | 216.3% | 125.3% | ||
| Low | 12.3% | 111.3% | 40.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -6.72 | -5.15 | -1.60 | ||
| Avg | -7.63 | -6.49 | -3.62 | ||
| Low | -8.67 | -7.80 | -8.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.